関連する実験動画

Updated: Feb 22, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

男性薬物乱用者における延長されたQTとTp-e間隔:横断研究からの洞察

Yusuf Hoşoğlu¹, Ahmet Doğru², Ayşe Hoşoğlu³

¹Department of Cardiology, Adıyaman University Training and Research Hospital, Adıyaman, Türkiye.

Cardiovascular journal of Africa

|February 20, 2026

まとめ

薬物乱用は,QT間隔の延長とQT (QTc) 間隔の修正に関連しており,不律症のリスクが増加しています. 修正されたTp-e区間は,薬物使用者の再極化問題を示すこともあります.

科学分野:

心臓病学心臓病学
薬理学薬理学とは
公衆衛生は公衆衛生である.

背景:

薬物乱用は,重大な心血管疾患のリスクをもたらします.
QTとTp-eの間隔のような心電図 (ECG) パラメータは,心臓の健康を評価するために重要である.
薬物乱用がECGパラメータに与える影響を理解することは,リスクの階層化に不可欠です.

研究の目的:

薬物乱用とECGパラメータ (QT,QTc,Tp-e間隔) の関連性を調査する.
薬物の乱用者における潜在的リズム障害を引き起こすリスクを評価する.
この集団におけるQT延長の予測要因を特定する.

主な方法:

126人の男性薬物乱用者と126人の対照群を比較した横断的研究.
QTを測定するために標準の12リードECG,バゼットとフリードリヒの方法を使用して修正されたQT (QTc),Tp-e間隔を使用しました.
グループを比較し,リスク要因を特定するために,多変数ロジスティック回帰を含む統計分析が行われました.

主要な成果:

薬物乱用者は,対照群と比較して,QTとQTcの間隔を大幅に延長した.
メタフェタミン使用者はQTcBが最長で,ヘロインと合成カンナビノイド使用者が次いでいました.
年齢,メタンフェタミンの使用,複数の物質の使用,特定の物質の使用期間/頻度によって予測されたQTc延長. 修正されたTp-ec間隔は,薬物乱用者の場合より長かった.

結論:

薬物乱用は,QTとQTcの間隔の延長と関連しており,心律不整のリスクが高まっていることを示しています.
修正されたTp-e区間は,薬物乱用者におけるリポラライゼーション異常の敏感なマーカーである可能性があります.
薬物使用者の心血管リスクのモニタリングのために,さらなる研究と臨床的警戒が推奨されます.

キーワード:

薬物関連障害薬物関連障害カナビノイドはカンナビノイドである.エレクトロカーディオグラフィーです.ヘロインヘロインヘロインヘロインヘロインメタンフェタミンは,メタンフェタミンの

さらに関連する動画

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

関連する概念動画

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Pharmacodynamic Models: Linear Concentration–Effect Model

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...